|
|
|
| Arsenic on cholesterol efflux and the expression of ABCA1, ABCG1 and SRBI |
| DI Chunhong*, ZHANG Yunheng, TAN Xiaohua, YANG Lei
|
| *The Clinical Laboratory of Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, China |
|
|
|
|
Abstract Objective To explore the impact of arsenic on cholesterol efflux and the expression of ATP-binding cassette, sub-family A, member 1 ( ABCA1 ), ATP-binding cassette transporter G1 ( ABCG1 ), and scavenger receptor class B member I ( SRBI ) in macrophages, so as to provide the evidence for the mechanism of arsenic induced atherosclerosis. Methods The human myeloid leukemia mononuclear cells ( THP-1 ), induced by phorbol myristate acetate, and mouse primary macrophages were treated with 0, 0.625, 1.25, 2.5 and 5 μmol/L NaAsO2 for 48 hours. Then the cells treated with 2.5 μmol/L NaAsO2 were changed to arsenic free mediums for 48 hours and collected every 12 hours to analyze the time effect of arsenic. The expression levels of ABCA1, ABCG1 and SRBI were determined by quantitative polymerase chain reaction and western blotting. Cholesterol efflux rates were measured by 3H isotope tracer. Results Arsenic significantly down-regulated the expression levels of ABCA1 and ABCG1, and cholesterol efflux in a dose-dependent manner. The levels of ABCA1 mRNA decreased by 69% and 72%, the levels of ABCG1 mRNA decreased by 42% and 34%, and the rate of cholesterol efflux decreased by 55% and 59% in THP-1 and mouse primary macrophages cells treated with 5 μmol/L NaAsO2 ( all P<0.05 ). Arsenic had no significant effect on SRBI expression ( all P>0.05 ). Arsenic inhibited ABCA1 expression and cholesterol efflux in THP-1 in a time-dependent manner. Compared with cells before the exposure of arsenic, the level of ABCA1 mRNA and the rate of cholesterol efflux in THP-1 bottomed at 48 hours by 43% and 42%, and gradually recovered when arsenic was removed. Conclusions Arsenic inhibits cholesterol efflux by down-regulating the expression of ABCA1 and ABCG1 in macrophages.
|
|
Received: 17 May 2021
Revised: 16 July 2021
Published: 30 September 2021
|
|
|
|
|
|
[1] GEBEL T W.Unanswered questions in arsenic toxicology[J]. J Environ Pathol Toxicol Oncol,2001,20(4):299-309.
[2] BALAKUMAR P,KAUR J.Arsenic exposure and cardiovascular disorders: an overview[J]. Cardiovasc Toxicol,2009,9(4):169-176.
[3] CHEN Y,WU F,GRAZIANO J H,et al.Arsenic exposure from drinking water,arsenic methylation capacity,and carotid intima-media thickness in Bangladesh[J]. Am J Epidemiol,2013,178(3):372-381.
[4] LEMAIRE M,LEMARIE C A,MOLINA M F,et al.Exposure to moderate arsenic concentrations increases atherosclerosis in ApoE-/- mouse model[J]. Toxicol Sci,2011,122(1):211-221.
[5] STATES J C,SRIVASTAVA S,CHEN Y,et al.Arsenic and cardiovascular disease[J]. Toxicol Sci,2009,107(2):312-323.
[6] MURPHY A J,DRAGOLJEVIC D,TALL A R.Cholesterol efflux pathways regulate myelopoiesis: a potential link to altered macrophage function in atherosclerosis [J/OL]. Front Immunol,2014,5:1-6.
[7] LANG J K,CIMATO T R.Cholesterol and hematopoietic stem cells: inflammatory mediators of atherosclerosis[J]. Stem Cells Transl Med,2014,3(5):549-552.
[8] CHENG T J,CHUU J J,CHANG C Y,et al.Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism[J]. Toxicol Appl Pharmacol,2011,256(2):146-153.
[9] MANNA P,SINHA M,SIL P C.Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid[J]. Arch Toxicol,2008,82(3):137-149.
[10] SASAKI M,KOMATSU T,IKEWAKI K.Impact of hepatic ABCA1(ATP-binding cassette transporter A1) deletion on reverse cholesterol transport a new clue in solving complex HDL (high-density lipoprotein) metabolism[J]. Arterioscler Thromb Vasc Biol,2019,39(9):1699-1701.
[11] BASHORE A C,LIU M,KEY C C,et al.Targeted deletion of hepatocyte Abca1 increases plasma HDL(high-density lipoprotein)reverse cholesterol transport via the LDL (low-density lipoprotein) receptor[J]. Arterioscler Thromb Vasc Biol,2019,39(9):1747-1761.
[12] WANG X,COLLINS H L,RANALLETTA M,et al.Macrophage ABCA1 and ABCG1,but not SR-BI,promote macrophage reverse cholesterol transport in vivo[J]. J Clin Invest,2007,117(8):2216-2224.
[13] 路倩,陈五军. 动脉粥样硬化中胆固醇外流的研究进展[J]. 生物化学与生物物理进展,2012,39(4):319-326.
[14] TAN X H,YANG L,XIAN L L,et al.ATP-binding cassette transporter A1(ABCA1)promotes arsenic tolerance in human cells by reducing cellular arsenic accumulation[J]. Clin Exp Pharmacol Physiol,2014,41(4):287-294.
[15] 罗燕,程建兵,谭晓华,等. 三磷酸腺苷结合盒转运体a1蛋白第二跨膜结构域缺失突变体的构建及其抗砷性研究[J]. 中国药学杂志,2012,47(23):1877-1882.
[16] TAVARES L S,RALPH M T,BATISTA J E C,et al. Perspectives for the use of latex peptidases from Calotropis procera for control of inflammation derived from Salmonella infections[J]. Int J Biol Macromol,2021,171:37-43.
[17] LIN G R,BORNFELDT K E.Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux[J]. Biochem Biophys Res Commun,2002,290(2):663-669.
[18] PADOVANI A M,MOLINA M F,MANN K K.Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro [J]. Arterioscler Thromb Vasc Biol,2010,30(6):1228-1236. |
|
|
|
